Company intelligence / Profile preview
BinDeBio
Shenzhen, Guangdong Sheng, Chinabindebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BinDeBio has multiple programs in development, with their Mesothelin CAR-T cell therapy and AS-1601 (targeting PD-1) both in Phase 2 clinical trials. Their Mesothelin CAR-T therapy is being tested for gastric cancer and pancreatic cancer.
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR-T cell therapiesTCR-T cellular immunotherapyNanobodyAntibodyBiological products
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
EurekaBioChinese Academy of SciencesVarious hospitals nationwide
Beyond the preview
Go deeper on BinDeBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BinDeBio.